Robert Hazlett
Stock Analyst at BTIG
(1.28)
# 3,707
Out of 5,140 analysts
23
Total ratings
39.13%
Success rate
-1.45%
Average return
Main Sectors:
Stocks Rated by Robert Hazlett
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AURA Aura Biosciences | Maintains: Buy | $21 → $24 | $5.48 | +337.96% | 3 | Oct 18, 2024 | |
| NKTR Nektar Therapeutics | Assumes: Buy | $60 | $36.92 | +62.51% | 2 | Sep 30, 2024 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $7 → $14 | $1.35 | +937.04% | 2 | May 9, 2024 | |
| LYRA Lyra Therapeutics | Maintains: Buy | $1,200 → $1,000 | $2.25 | +44,344.44% | 1 | Feb 7, 2023 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $62 → $98 | $189.10 | -48.18% | 2 | Dec 23, 2022 | |
| VSTM Verastem | Maintains: Buy | $96 → $60 | $6.36 | +843.40% | 3 | Oct 5, 2022 | |
| CMPS COMPASS Pathways | Initiates: Buy | $63 | $7.00 | +800.00% | 1 | May 27, 2021 | |
| PRTA Prothena Corporation | Upgrades: Buy | $29 | $9.68 | +199.59% | 4 | Feb 2, 2021 | |
| RDHL RedHill Biopharma | Initiates: Buy | $26,000 | $1.35 | +1,925,825.93% | 1 | Sep 11, 2020 | |
| AKBA Akebia Therapeutics | Maintains: Buy | $26 → $6 | $1.37 | +337.96% | 2 | Sep 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $15.91 | +13.14% | 2 | Aug 31, 2017 |
Aura Biosciences
Oct 18, 2024
Maintains: Buy
Price Target: $21 → $24
Current: $5.48
Upside: +337.96%
Nektar Therapeutics
Sep 30, 2024
Assumes: Buy
Price Target: $60
Current: $36.92
Upside: +62.51%
Rani Therapeutics Holdings
May 9, 2024
Maintains: Buy
Price Target: $7 → $14
Current: $1.35
Upside: +937.04%
Lyra Therapeutics
Feb 7, 2023
Maintains: Buy
Price Target: $1,200 → $1,000
Current: $2.25
Upside: +44,344.44%
Axsome Therapeutics
Dec 23, 2022
Maintains: Buy
Price Target: $62 → $98
Current: $189.10
Upside: -48.18%
Verastem
Oct 5, 2022
Maintains: Buy
Price Target: $96 → $60
Current: $6.36
Upside: +843.40%
COMPASS Pathways
May 27, 2021
Initiates: Buy
Price Target: $63
Current: $7.00
Upside: +800.00%
Prothena Corporation
Feb 2, 2021
Upgrades: Buy
Price Target: $29
Current: $9.68
Upside: +199.59%
RedHill Biopharma
Sep 11, 2020
Initiates: Buy
Price Target: $26,000
Current: $1.35
Upside: +1,925,825.93%
Akebia Therapeutics
Sep 4, 2020
Maintains: Buy
Price Target: $26 → $6
Current: $1.37
Upside: +337.96%
Aug 31, 2017
Initiates: Buy
Price Target: $18
Current: $15.91
Upside: +13.14%